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Abstract
Background To describe trajectories of health‐related quality of life (QoL), life satisfaction,
and psychological adjustment for men with prostate cancer over the medium to long term and
identify predictors of poorer outcomes using growth mixture models.
Methods One‐thousand sixty‐four (82.4% response) men diagnosed with prostate cancer
were recruited close to diagnosis and assessed over a 72‐month (6‐year) period with self‐report
assessment of health‐related QoL, life satisfaction, cancer‐related distress, and prostate specific
antigen anxiety. Urinary, bowel, and sexual function were also assessed using validated
questionnaires.
Results Poorer physical QOL was predicted by older age, lower education, lower income,
comorbidities, and receiving hormone therapy. Lower life satisfaction was related to younger
age, lower income, not being partnered, and comorbidities. Poorer psychological trajectories were
predicted by younger age, lower income, comorbidities, and receiving radical prostatectomy or
brachytherapy. Better urinary, bowel, and sexual function were related to better global outcomes
over time. Anxiety about prostate specific antigen testing was rare.
Conclusions Distinct trajectories exist for medium‐ to long‐term QoL, life satisfaction, and
psychological adjustment after prostate cancer; with age and socioeconomic deprivation playing
a differential role in men’s survivorship profile and the impact of functional status on outcomes
increasing over time. These results reinforce the need for an appraisal of men’s life course in
addition to treatment side effects when planning survivorship care after cancer.
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1 | INTRODUCTION
Prostate cancer is the most common cancer among men in developed
countries, with an estimated 740 000 men diagnosed in these
countries in 2012 alone (75% of global incidence).1 Five‐year relative
survival for this cancer now approaches 100% in some countries for
those diagnosed at a localised stage,2 although there were still an esti-
mated 140 000 deaths due to prostate cancer in developed countries
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in 2012.1 There is often a long time frame between prostate cancer
diagnosis and death, with men continuing to have excess mortality
up to 15 years after diagnosis,3 and dying from their prostate cancer
more than 20 years after diagnosis.4 This means prostate cancer
survivorship for many men is a long‐lived experience, with quality
of life (QoL) and psychological well‐being crucial considerations in
care after diagnosis. To date, there is limited data on long‐term
survivorship (>5 years post diagnosis) in general, and this is more
so with regards to the survivorship experience of men with prostate
cancer.5
To date, the domain‐specific QoL effects of treatment for prostate
cancer have been well described. These include urinary, bowel, and
sexual dysfunction, as well as effects specific to hormone ablation
therapy with these effects differing by treatment approach. For exam-
ple, 5 years after diagnosis men treated with radical prostatectomy
(RP) experience worse urinary incontinence, but similar sexual out-
comes, compared to men treated with radiation therapy.6 By contrast,
men treated with radiation therapy experience more long‐term
adverse effects on bowel function with androgen deprivation having
the greatest adverse effect on physical QoL.7 Studies relating to overall
health‐related QoL suggest that men’s mental and physical wellbeing
are stable in the medium to long term. However, the predominant
focus on domain‐specific effects leaves gaps in our understanding of
the impact of prostate cancer on men’s global QoL and may obscure
patient subgroups who do not fare well over time.
Even less is known about the course of long‐term psychological
adjustment after prostate cancer, with distress estimates close to
diagnosis varying from 10% to 23%.8 Depression and anxiety seem
to be highest at treatment commencement for men with localised
and locally advanced prostate cancer, reducing to levels below or
similar to that of the general population after 12 months.9 To date,
there is scant research examining long‐term (>5 years) psychological
adjustment after prostate cancer, with limitations including the use of
non‐validated asesssments.10 For those studies that did apply well
validated measures, 1 group reported that 10% of men with localised
prostate cancer experience clinically significant depression up to
8 years after treatment.11 By contrast, Korfage et al (2006) reported
that one in 4 men (28%) with prostate cancer were highly anxious
before treatment; although by 6 months, this reduced with most men
experiencing low distress at 5 years.12 These studies however were
not able to assess for heterogeneity in trajectories of adjustment and
so were limited in their ability to longitudinally identify risk factors
for distress and patterns of change.
In this regard, growth mixture models (GMMs) have been widely
used to assess for heterogeneity of trajectories of scores within a
population.13 Growth mixture models allow different statistical distri-
butions for analysing various types of score variables, the identification
of differential features among trajectory classes, and the inclusion of
time‐varying covariates for modelling the association between the
score variable and predictors at each measurement time point.14,15
By applying this approach in our previous research with colorectal
cancer patients, we identified unique patterns of risk that were associ-
ated with distinct psychological adjustment and QoL trajectories.16,17
To date, to our knowledge, this approach has not been applied to
examine men’s adjustment to prostate cancer.
Thus, our aim in the current study was to examine the trajectories
of health‐related QoL, life satisfaction, and psychological adjustment
in men previously diagnosed with prostate cancer who were
followed over a 6‐year period. We examined socio‐demographic
predispositional and clinical factors as well as time varying functional
outcomes as predictors to identify characteristics of men “at risk” for
poorer outcomes across treatment types.
2 | METHOD
2.1 | Participants
These data are from a longitudinal study of men newly diagnosed with
prostate cancer in Queensland.18–20 Ethical approval was obtained
from the Queensland University of Technology Human Research
Ethics Committee and ethics committees of 10 public hospitals in
Queensland. Men newly diagnosed with prostate cancer from the
geographic catchment areas of South East and North Queensland,
Australia, were recruited between March 2005 and September 2007.
Eligibility criteria included ability to read, write, and speak English; no
history of dementia, head injury or psychiatric illness; and regular
access to a telephone. Urologists referred men to the study if they
were newly diagnosed with prostate cancer irrespective of stage of
disease. Of the 1291 men referred to the study, 1064 (82.4%) were
eligible and consented to participate. Participants completed assess-
ments at baseline, and 2, 6, 12, 24, 36, 48, 60, and 72 months after
the start of treatment. Baseline assessments were completed for
1034 (97%) men. In all, 575 (54% from eligible and consented) men
completed assessments at all 9 time points, with 357 men withdrawing
from the study between baseline and 72 month assessment.
Self‐report measures were administered by mail at each time point.
Of the total sample, 41 men had died at 6 years. Other reasons for
attrition included being too unwell, not contactable, and not wanting
to think about prostate cancer anymore.
2.2 | Predictor variables
Socio‐demographic variables including age, marital status, education
and income, and clinical variables such as chronic health conditions,
treatment type, time since diagnosis, prostate specific antigen (PSA),
Gleason score, and stage were collected at baseline.
2.3 | Outcome variables
2.3.1 | Quality of life
The Short Form 36 (SF‐36) assessed health‐related QoL.21 Two global
measures of psychological and physical functioning are derived (mental
health domain and physical health domain) whereby higher scores
indicate better health‐related QoL.
Disease‐specific QoL was measured using the expanded prostate
cancer index composite (EPIC)22 assessing urinary, bowel, and sexual
function domains. All EPIC scores were standardised to a 0 to 100
scale. Higher scores indicate better QoL. Internal reliability among
the 3 EPIC function summary scores ranged from α = 0.76 to 0.95
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(urinary, α = 0.83 to 0.86; bowel, α = 0.83 to 0.90; and sexual, α = 0.90
to 0.95).
2.3.2 | Satisfaction with life
The satisfaction with life scale (SWL)23 assessed participants’ subjec-
tive cognitive well‐being (α = 0.88 to 0.91). Higher scores indicate a
higher satisfaction with life.
2.3.3 | Cancer‐related distress
The revised impact of event scale (RIES)24 assessed cancer‐specific
distress at baseline through to 60 months. The RIES contains 3
subscales: intrusion (α = 0.87 to 0.91), avoidance (α = 0.84 to 0.87),
and hyperarousal (α = 0.83 to 0.87). Higher scores indicate higher
cancer‐specific distress. The RIES was not administered after 5 years
to reduce participant burden.
The PSA anxiety subscale of the memorial anxiety for prostate
cancer (MAX‐PC) scale25,26 assessed distress related to PSA testing
(α = 0.60 to 0.77). Higher scores indicate higher distress.
2.4 | Statistical analyses
Growth mixture models in Mplus Version 6.1215,27 were used to iden-
tify trajectory classes and predictors of membership in these classes,
separately for the QoL SF36 (physical health domain and mental health
domain), the SWL score, and the cancer‐related distress RIES score.
Nonlinear GMMs (consisting of intercept, slope, and quadratic growth
parameters) were adopted to model individual growth trajectories
from unobserved (latent) subpopulations, where individual variation
in growth parameters (intercept and slope) was captured by random
effects with different variance components.14,28 The association
between the EPIC (urinary, bowel, and sexual) functions and outcome
variables at each of the time points was modelled by including the 3
function subscales in the GMMs as time‐varying covariates at each
time point.13
The RIES scores were heavily right‐skewed, with around 10‐45%
of 0 scores at each of the time points. Thus, the GMMs with Poisson
and negative binomial distributions (including 0‐inflated models) were
considered for the longitudinal analysis of the RIES scores over time.15
Model selection was determined using the Bayesian information
criterion.29
With GMMs, the initialization of growth parameters was obtained
by implementing a latent class growth analysis (assuming no within‐
class variance) fitted to the data. The GMM analyses were
implemented with 100 random sets of starting values and 10 final opti-
mizations. The number of trajectory classes K was determined using
the Lo‐Mendell‐Rubin likelihood ratio test statistic.30 Covariates were
then entered into the K‐class (unconditional) GMM via multinomial
logistic regression that compares the reference class (high‐SF36
domain or SWL scores, or low RIES score) with the other trajectory
classes (lower SF36 domain or SWL scores, or higher RIES scores).
Missing data in outcome variables (SF36 domain, SWL, and RIES
scores) were handled in Mplus using a robust full information maxi-
mum likelihood estimation procedure with the missing at random
assumption that the missing scores are unrelated to the outcome
variables.30 Estimates of covariance coverage for each pair of variables
were checked for evaluating the impact of missing data in outcome
variables on model convergence. Missing values in the EPIC
time‐varying covariates were computed using the multiple imputation
method with restriction to a 0 to 100 scale.31 In the first stage, the
missing EPIC subscales were imputed based on the characteristics of
the observed EPIC subscales, and this procedure was repeated 10
times to generate 10 imputed data sets. In the second stage, the
GMMs were fitted separately to each of the imputed data sets and
the results were pooled into a final set of estimates.31,32 Individuals
(N = 120) with more than 6 missing values in the EPIC time‐varying
covariates were excluded for the analyses. This reduced the sample
size from 1064 to 944 in the GMMs. Patients with missing values in
other covariates were also excluded in the analyses.
Due to the fact that the proportion of 0 MAX‐PC scores was very
high at each time point (79‐93%), it is not possible to obtain a robust
estimation of GMMs (with 0‐inflated models) for the longitudinal anal-
ysis of MAX‐PC scores. Thus, descriptive statistical analyses were per-
formed to illustrate the distribution of MAX‐PC scores over time.
3 | RESULTS
Demographic and clinical characteristics of the study samples are pro-
vided in Table 1. The mean age of men at recruitment was 63.7 years;
82.7% were married with the remainder divorced, widowed, or never
married; 53.3% had completed trade or university education, and the
remainder had high school or less schooling; 43% had an annual
income of $40 000AUS or less, 24.7% between $40 000 to
$80 000AUS and 21.9% > $80 000AUS. The average self‐reported
PSA level at baseline was 11.0; the average Queensland cancer registry
Gleason score was 7; the average time since diagnosis at recruitment
was 142 days; 92.1% of men had localized stage disease; 6.3% had
locally advanced stage; only 1.6% had advanced stage; 46.3% had
received a RP; 38.3% had external beam radiation therapy; and
16.7% had received brachytherapy (BT).
3.1 | Quality of life: physical health
Three distinct classes of trajectory patterns were identified for the
QoL SF36 (physical health domain) using GMM (Figure 1A). The
constant high QoL class (Class 3) indicates a group of patients
(50.3%) who had constantly high physical health throughout the
6‐year follow‐up period. Class 2 represents a group of patients
(30.2%) whose physical health started at a medium level and then
at 3 years post‐diagnosis began to decrease. Class 1 (19.5% of
patients) indicates a physical health trajectory pattern, which
decreased steadily from a medium level and then increased at
4 years post‐diagnosis.
Three predictors that significantly (P < .05) differentiated the
physical health trajectory classes with the constant high QoL (Class 3)
as the comparison class were identified within the GMMs (Table 2A).
In comparison with the constant high QoL class, Class 2 (medium
decrease) was characterized by patients with high levels of comorbid-
ity (adjusted odds ratio [OR] = 2.26, 95% confidence interval
[CI] = 1.09‐4.68 for 1‐2 conditions; adjusted OR = 6.81, 95%
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CI = 2.80‐16.5 for ≥3 conditions) and patients who did not receive
RP (adjusted OR = 0.24, 95% CI = 0.10‐0.57) or BT (adjusted
OR = 0.24, 95% CI = 0.11‐0.55). Class 2 was also characterized by
patients who received hormone therapy (adjusted OR = 2.39, 95%
CI = 1.08‐5.31). Compared to the constant high QoL class, Class 1
was differentiated by patients with lower household income
(adjusted OR = 12.76, 95% CI = 2.48‐65.7 for income <$40 000;
adjusted OR = 9.15, 95% CI = 1.70‐49.3 for income between
$40 000 and $80 000), patients with ≥3 comorbid conditions
(adjusted OR = 9.51, 95% CI = 3.84‐23.5), and patients who did
not receive RP (adjusted OR = 0.13, 95% CI = 0.05‐0.34) or BT
(adjusted OR = 0.25, 95% CI = 0.10‐0.59). Moreover, Class 1 was
characterized by patients who received hormone therapy (adjusted
OR = 2.95, 95% CI = 1.29‐6.71).
3.2 | Quality of life: mental health
Three distinct classes of trajectory patterns were identified for the
QoL SF36 (mental health domain) using GMM (Figure 1B). The
Constant High QoL class (Class 3) indicates a group of patients
(62.3%) who had constantly high mental health throughout the 6 year
follow‐up period. Class 2 represents a group of patients (20.4%) whose
mental health increased initially and then at 3‐years post‐diagnosis
began to decrease. Class 1 (17.3% of patients) indicates a mental
health trajectory pattern which decreased initially and then increased
at 3‐years post‐diagnosis.
Two predictors that significantly (P < .05) differentiated the mental
health trajectory classes with the constant high QoL as the comparison
class were identified within the GMMs (Table 2B). Compared to the
constant high QoL class, Class 2 was characterized by patients with
high levels of comorbidity (adjusted OR = 2.69, 95% CI = 1.18‐6.12
for 1‐2 conditions; adjusted OR = 3.84, 95% CI = 1.51‐9.75 for ≥3
conditions). Compared to the constant high QoL class, Class 1 was
differentiated by patients with household income <$40 000 (adjusted
OR = 2.55, 95% CI = 1.30‐5.00) and patients with ≥3 comorbid
conditions (adjusted OR = 3.26, 95% CI = 1.50‐7.07).
3.3 | Satisfaction with life
Three distinct classes of trajectory patterns were identified for SWL
using GMM (Figure 1C). The constant high SWL class (Class 3)
indicates a group of patients (63.0%) who had constantly high SWL
throughout the 6‐year follow‐up period. Class 2 represents a group
of patients (31.8%) whose SWL was maintained at a low level
constantly. Class 1 (5.2% of patients) indicates a SWL trajectory
pattern, which decreased from a medium level and then increased at
3‐years post‐diagnosis.
Four predictors that significantly (P < .05) differentiated the SWL
trajectory classes with the constant high satisfaction as the comparison
class were identified within the GMMs (Table 2C). In comparison with
the constant high satisfaction class, Class 2 (low constant) was charac-
terized by patients who were never married/widowed/divorced/sepa-
rated (adjusted OR = 2.68, 95% CI = 1.61‐4.48), younger age (adjusted
OR = 1.10 per 1‐year decrease in age, 95% CI = 1.06‐1.13), and
patients with household income <$40 000 (adjusted OR = 2.24, 95%
CI = 1.24‐4.05) and ≥3 comorbid conditions (adjusted OR = 3.17,
95% CI = 1.73‐5.80).
3.4 | Cancer‐related distress
Three distinct classes of trajectory patterns were identified for can-
cer‐related distress (RIES) using GMM with a negative binomial
TABLE 1 Demographic and clinical characteristics of study samples
(N = 1064)
Characteristics Count (%) or Mean (SD)
Age at recruitment (years) 63.7 (7.8)
Marital status
Married/defacto 880 (82.7%)
Divorced/separated 110 (10.4%)
Widowed 27 (2.5%)
Never married 47 (4.4%)
Education level
Primary school/not complete
primary
145 (13.6%)
Junior high school 247 (23.3%)
Senior high school 104 (9.8%)
Trade/diploma 366 (34.5%)
University 200 (18.8%)
Missing 2
Household income
<$40 000 454 (43.0%)
$40 000‐$80 000 261 (24.7%)
>$80 000 231 (21.9%)
Not answer/don’t know 110 (10.4%)
Missing 8
PSA level at diagnosis 11.0 (27.5)
Missing 151
QCR Gleason score 7.0 (0.9)
Missing 70
Time since diagnosis at recruitment
(days)
142 (254)
Stage
Localized 978 (92.1%)
Locally advanced 67 (6.3%)
Advanced 17 (1.6%)
Missing 2
Comorbidity
0 conditions 175 (16.6%)
1‐2 conditions 556 (52.8%)
≥3 conditions 323 (30.6%)
Missing 10
Therapy performed
Radical prostatectomy 493 (46.3%)
External beam radiation 407 (38.3%)
Brachytherapy 178 (16.7%)
Hormone therapy 385 (36.2%)
Watchful waiting 59 (5.5%)
Abbreviations: PSA, prostate specific antigen; QCR, Queensland cancer
registry.
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model (Figure 1D). Cancer‐related distress dropped significantly in
the first half year of the follow‐up period for all 3 classes. The low
cancer‐related distress class (Class 3) indicates a group of patients
(39.0%) who had low cancer‐related distress throughout the 5 year
follow‐up period. Class 2 represents a group of patients (49.2%)
whose cancer‐related distress maintained at a medium level. Class 1
(11.8% of patients) indicates a cancer‐related distress trajectory
pattern, which was maintained at a higher level.
Three predictors that significantly (P < .05) differentiated the
cancer‐related distress trajectory classes with the low RIES score as
the comparison class were identified within the GMMs (Table 2D). In
comparison with the low RIES class, Class 2 (medium RIES) was
characterized by patients who were younger in age (adjusted OR = 1.03
per 1‐year decrease in age, 95% CI = 1.00‐1.06) and who received RP
(adjusted OR = 2.28, 95% CI = 1.11‐4.69) or BT (adjusted OR = 2.30,
95% CI = 1.35‐3.91). Compared to the low RIES class, Class 1 (high
RIES) was differentiated by patients who were younger in age (adjusted
OR = 1.08 per 1‐year decrease in age, 95% CI = 1.04‐1.13) and had high
levels of comorbidity (adjusted OR = 3.56, 95% CI = 1.31‐9.65 for 1‐2
conditions; adjusted OR = 5.57, 95% CI = 1.92‐16.1 for ≥3 conditions).
FIGURE 1 Trajectory patterns identified using growth mixture models: A, quality of life SF36, physical health domain (N = 928); B, quality of life
SF36, mental health domain (N = 928); C, satisfaction with life (SWL) score (N = 928); D, cancer‐related distress revised impact of event scale (RIES)
score (N = 934)
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TABLE 2 Predictors of trajectory class membership for various outcome measures
Predictor
Adjusted OR (95% CI) relative to constant high class (Class 3)
P valuea
Class 2 Class 1
(A) Quality of life SF36 (physical health domain, N = 928)
Household income <.001
<$40 000 1.83 (0.96, 3.47) 12.76* (2.48, 65.7)
$40 000‐$80 000 1.33 (0.59, 3.00) 9.15* (1.70, 49.3)
>$80 000 Reference Reference
Not answer/do not know 1.71 (0.70, 4.20) 5.30 (0.83, 33.8)
Comorbidity <.001
0 condition Reference Reference
1‐2 conditions 2.26* (1.09, 4.68) 1.99 (0.88, 4.52)
≥3 conditions 6.81* (2.80, 16.5) 9.51* (3.84, 23.5)
Therapy performed vs nil <.001
Radical prostatectomy 0.24* (0.10, 0.57) 0.13* (0.05, 0.34)
External beam radiation 1.02 (0.51, 2.04) 0.43 (0.18, 1.00)
Brachytherapy 0.24* (0.11, 0.55) 0.25* (0.10, 0.59)
Hormone therapy 2.39* (1.08, 5.31) 2.95* (1.29, 6.71)
Watchful waiting 1.12 (0.41, 3.08) 0.49 (0.16, 1.56)
(B) Quality of life SF36 (mental health domain, N = 928)
Household income .008
<$40 000 1.44 (0.74, 2.82) 2.55* (1.30, 5.00)
$40 000‐$80 000 1.40 (0.72, 2.71) 1.33 (0.62, 2.85)
>$80 000 Reference Reference
Not answer/don’t know 0.84 (0.32, 2.24) 1.33 (0.49, 3.61)
Comorbidity <.001
0 conditions Reference Reference
1‐2 conditions 2.69* (1.18, 6.12) 1.71 (0.82, 3.58)
≥3 conditions 3.84* (1.51, 9.75) 3.26* (1.50, 7.07)
(C) Satisfaction with life (SWL, N = 928)
Age (younger) 1.10* (1.06, 1.13) 1.00 (0.93, 1.08) <.001
Marital status <.001
Married/defacto Reference Reference
Never married/widowed/divorced/separated 2.68* (1.61, 4.48) 1.07 (0.34, 3.33)
Household income .022
<$40 000 2.24* (1.24, 4.05) 1.85 (0.60, 5.74)
$40 000‐$80 000 1.40 (0.81, 2.44) 0.80 (0.24, 2.75)
>$80 000 Reference Reference
Not answer/don’t know 0.91 (0.41, 2.00) 0.57 (0.10, 3.31)
Comorbidity <.001
0 conditions Reference Reference
1‐2 conditions 1.74 (0.99, 3.04) 0.83 (0.35, 1.98)
≥3 conditions 3.17* (1.73, 5.80) 0.29 (0.07, 1.28)
(D) Cancer‐related distress (RIES, N = 934)
Age (younger) 1.03* (1.00, 1.06) 1.08* (1.04, 1.13) <.001
Comorbidity <.001
0 conditions Reference Reference
1‐2 conditions 1.02 (0.65, 1.58) 3.56* (1.31, 9.65)
≥3 conditions 1.09 (0.64, 1.85) 5.57* (1.92, 16.1)
Therapy performed vs nil .003
(Continues)
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3.5 | PSA anxiety
The proportion of 0 MAX‐PC scores or PSA anxiety was high at each
time point. In brief, 79.1% of patients had 0 PSA anxiety at baseline,
and this increased gradually during the follow‐up period. At 6‐years
post‐diagnosis, the proportion of men with no PSA anxiety was
92.6%. For those patients with PSA Anxiety (nonzero MAX‐PC scores),
the mean score was 2.33 at baseline, which declined slightly during the
follow‐up period (however, an increase of mean scores was observed
at 1‐ and 4‐years post‐diagnosis). At 6‐years post‐diagnosis, the mean
PSA Anxiety score was 2.08. The improvement in PSA anxiety was also
reflected by the lowered maximum PSA anxiety among the patients.
From 5‐years post‐diagnosis, there were no patients with PSA anxiety
scores greater than 6.
3.6 | Time‐varying effects of the EPIC subscales
The effects of the EPIC urinary, bowel, and sexual function on the 4
outcome variables at each of the time points are displayed in
Figure 2. Generally, higher EPIC function significantly increased the
patient’s QoL, SWL, and reduced cancer‐related distress. The effects
of bowel function on physical and mental health and cancer‐related
distress were larger compared to urinary and sexual function. For can-
cer‐related distress, the effects of the EPIC functions were larger
approximately 24‐36 months post‐diagnosis, relative to the effects just
after diagnosis (Figure 2D). This indicates that the effects of function
on cancer‐related distress increases over time.
4 | DISCUSSION
The present results suggest particular characteristics for men with a
diagnosis of prostate cancer that predict, over the medium and long
term, poorer QoL and psychological outcomes. First, if men are youn-
ger at the time of diagnosis, they can be expected to be at greater risk
for experiencing higher cancer‐related distress and poorer life satisfac-
tion. There are a number of reasons why younger men may be more
likely to experience these outcomes that reflect the greater disruption
of life goals and circumstances when cancer occurs at a younger age.33
Younger men may still be building or consolidating careers, be more
sexually active, and have greater financial responsibilities than older
men. From this, the burden of cancer, and the uncertainty and
psychological demands that come with living with cancer, may be
heightened. Similar to previous research,34 older men were more at
risk for poorer physical QoL that may link to the comorbidities associ-
ated with age that increase the physical challenges of treatment.
Indeed, comorbidities themselves were associated with poorer physi-
cal and mental well‐being highlighting the burden of chronic illness
more broadly in this patient population. For QoL, life satisfaction and
psychological distress, the man’s income and level of education were
variously associated with poorer outcomes, reflecting the important
role of economic advantage as a coping resource. This finding is also
consistent with previous research showing men with low health liter-
acy are more vulnerable to poorer mental health after prostate can-
cer.35 Finally, men who were un‐partnered were also at risk of
greater psychological distress, with this a likely indicator of low social
support. From this, we propose that an appraisal of a man’s life course
and situation is an essential first step for an effective and well‐targeted
survivorship plan.33
We observed, over time, an increasing negative effect of poor
sexual, urinary, and bowel function on cancer‐specific distress, peaking
at 2‐ to 3‐years post diagnosis. Impacts of these areas of function for
many men are long term, and these data suggest that rather than
men learning to live with it, functional deficits over time may amplify
avoidant and intrusive thinking about cancer, as well as hyperarousal
or physical symptoms of distress. This is particularly striking given
the relative absence in this large cohort of PSA anxiety, although this
finding may reflect that rather than being pervasive, PSA anxiety is
centred more around specific time points (eg, clinical checkups).
Sexual, urinary, and bowel function therefore may be of more concern
to men over the course of their survivorship experience than frequent
PSA testing, and this may have implications for decision making about
surveillance approaches to early prostate cancer. Finally, hormone
therapy was associated with poorer physical well‐being, underlining
the burden this treatment type carries for men with prostate cancer.
Receiving RP or BT was predictive of men experiencing some cancer‐
related distress; however, the reasons for this are unclear.
Importantly, it is clear that the course of adjustment for many men
will not be linear. Ongoing assessment of function as well as QoL and
psychological distress is needed into the medium and long term, with
linked accessible support systems. In many settings, this will require
the integration of primary and community care services as men leave
the acute treatment system. To date, peer support has been a leading
TABLE 2 (Continued)
Predictor
Adjusted OR (95% CI) relative to constant high class (Class 3)
P valuea
Class 2 Class 1
Radical prostatectomy 2.28* (1.11, 4.69) 0.56 (0.17, 1.81)
External beam radiation 2.30* (1.35, 3.91) 0.54 (0.21, 1.36)
Brachytherapy 0.98 (0.56, 1.71) 0.39 (0.13, 1.17)
Hormone therapy 1.15 (0.64, 2.09) 1.38 (0.65, 2.94)
Watchful waiting 2.14 (0.90, 5.12) 0.77 (0.15, 4.01)
Abbreviations: CI, confidence interval; OR, odds ratio; RIES, revised impact of event scale; SWL, satisfaction with life scale.
*significant at 0.05 level on the adjusted log odds of being in the class versus Class 3
alikelihood ratio test (full model versus model without the predictor under consideration)
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model of care in the community36,37 and it seems likely that as preva-
lence and the health costs of prostate cancer increase, so too will the
importance of peer support in survivorship care. Future research to
develop and evaluate integrated long‐term survivorship care systems
is needed.
Limitations of the current study include the use of a nonrepresen-
tative sample and the extent of study attrition over time. Specifically,
the cohort was more likely to be have been diagnosed with intermedi-
ate than advanced prostate cancer compared to all men diagnosed
with prostate cancer in Queensland during the same period.20 This
means that generalisability to the population should be approached
cautiously and that we were unable to explore the effect of stage of
illness on outcomes. As well, we did not have matched controls as a
comparison group. As a further comment, masculinity is increasingly
acknowledged as influential in men’s response to prostate cancer.38
There is a need for future research to include masculinity as a potential
mediator or moderator of adjustment outcomes that will be aided by
the recent development of a context specific measure for this
purpose.38 Study strengths include the high response rate, large sam-
ple, application of well validated and reliable measures, and long‐term
(>5 years) follow‐up. In addition, the application of GMMs presents a
new picture of posttreatment adjustment not previously presented,
providing a more accurate picture of differences in individual change
over time than the conventional growth model and the latent class
FIGURE 2 Effects from the expanded prostate cancer index composite (EPIC) urinary, bowel, and sexual functions on A, SF36 physical health, B,
SF36 mental health, C, satisfaction with life (SWL), and D, revised impact of event scale (RIES): a positive value of effects means that a higher EPIC
function increases the score of the outcome variable, while a negative value indicates that a higher EPIC function decreases the score of the
outcome variable
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growth analysis method while allowing also for nonlinear change to be
described.
In conclusion, prostate cancer survivorship is a neglected area of
research.39 Medium‐ to long‐term survivorship care plans for men with
prostate cancer will need to consider the influence of age, partner
status, and social disadvantage and comorbidities, as well as urinary,
sexual, and bowel function, on men’s QoL and psychological outcomes.
A holistic approach that considers life course as well as medical
treatment regimens is needed. For many men, the path of recovery
and survivorship will not be linear, with the implication that regular
assessment of progress towards optimal well‐being is needed over
the medium to long term, with care plans adjusted to meet emerging
issues.
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